

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2024 January 14; 30(2): 115-198



## Contents

Weekly Volume 30 Number 2 January 14, 2024

## REVIEW

- 115 Small nucleolar RNA and its potential role in the oncogenesis and development of colorectal cancer  
*Lan YZ, Wu Z, Chen WJ, Fang ZX, Yu XN, Wu HT, Liu J*

## MINIREVIEWS

- 128 Hepatocardiorenal syndrome in liver cirrhosis: Recognition of a new entity?  
*Wu HHL, Rakisheva A, Ponnusamy A, Chinnadurai R*
- 137 Esophageal intramural pseudodiverticulosis  
*Shintaku M*

## ORIGINAL ARTICLE

## Retrospective Cohort Study

- 146 Long-term prognosis and its associated predictive factors in patients with eosinophilic gastroenteritis  
*Li KW, Ruan GC, Liu S, Xu TM, Ma Y, Zhou WX, Liu W, Zhao PY, Du ZR, Li J, Li JN*

## Retrospective Study

- 158 Association of tumor budding with clinicopathological features and prognostic value in stage III-IV colorectal cancer  
*Luo YH, Yan ZC, Liu JY, Li XY, Yang M, Fan J, Huang B, Ma CG, Chang XN, Nie X*
- 170 Automatic detection of small bowel lesions with different bleeding risks based on deep learning models  
*Zhang RY, Qiang PP, Cai LJ, Li T, Qin Y, Zhang Y, Zhao YQ, Wang JP*

## Observational Study

- 184 Success of susceptibility-guided eradication of *Helicobacter pylori* in a region with high secondary clarithromycin and levofloxacin resistance rates  
*Wang YM, Chen MY, Chen J, Zhang XH, Feng Y, Han YX, Li YL*

## LETTER TO THE EDITOR

- 196 Gastric cancer immunotherapy: A scientometric and clinical trial review  
*Du QC, Wang XY, Yu H*

**ABOUT COVER**

Editorial Board Member of *World Journal of Gastroenterology*, Matjaž Homan, MD, PhD, Associate Professor, Department of Gastroenterology, Hepatology and Nutrition, University Children's Hospital, Faculty of Medicine, University of Ljubljana, Ljubljana 1000, Slovenia. matjaz.homan@kclj.si

**AIMS AND SCOPE**

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

**INDEXING/ABSTRACTING**

The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE), MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJG as 4.3; Quartile category: Q2. The WJG's CiteScore for 2021 is 8.3.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Hua-Ge Yu; Production Department Director: Xiang Li; Editorial Office Director: Jia-Ru Fan.

**NAME OF JOURNAL**

*World Journal of Gastroenterology*

**ISSN**

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

**LAUNCH DATE**

October 1, 1995

**FREQUENCY**

Weekly

**EDITORS-IN-CHIEF**

Andrzej S Tarnawski

**EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF**

Xian-Jun Yu (Pancreatic Oncology), Jian-Gao Fan (Chronic Liver Disease), Hou-Bao Liu (Biliary Tract Disease)

**EDITORIAL BOARD MEMBERS**

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

**PUBLICATION DATE**

January 14, 2024

**COPYRIGHT**

© 2024 Baishideng Publishing Group Inc

**PUBLISHING PARTNER**

Shanghai Pancreatic Cancer Institute and Pancreatic Cancer Institute, Fudan University  
Biliary Tract Disease Institute, Fudan University

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/gerinfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/gerinfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**POLICY OF CO-AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/310>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/gerinfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>

**PUBLISHING PARTNER'S OFFICIAL WEBSITE**

<https://www.shca.org.cn>  
<https://www.zs-hospital.sh.cn>



## Gastric cancer immunotherapy: A scientometric and clinical trial review

Qian-Cheng Du, Xin-Yu Wang, Hua Yu

**Specialty type:** Gastroenterology and hepatology

**Provenance and peer review:**

Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Kotelevets SM, Russia

**Received:** November 11, 2023

**Peer-review started:** November 11, 2023

**First decision:** December 20, 2023

**Revised:** December 21, 2023

**Accepted:** December 28, 2023

**Article in press:** December 28, 2023

**Published online:** January 14, 2024



**Qian-Cheng Du**, Thoracic Surgery, Shanghai Xuhui Central Hospital, Shanghai 200031, China

**Xin-Yu Wang**, Thyroid, Breast and Vascular Surgery, Shanghai Fourth People's Hospital Affiliated to Tongji University School of Medicine, Shanghai 200434, China

**Hua Yu**, Department of General Surgery, Shanghai Fourth People's Hospital Affiliated to Tongji University School of Medicine, Shanghai 200434, China

**Corresponding author:** Hua Yu, MM, Associate Chief Physician, Department of General Surgery, Shanghai Fourth People's Hospital Affiliated to Tongji University School of Medicine, No. 1279 Sanmen Road, Hongkou District, Shanghai 200434, China.  
[luckyhuhua@163.com](mailto:luckyhuhua@163.com)

### Abstract

This letter is intended to arouse your interest in a recent review of comprehensive scientometrics and clinical trials on immunotherapy for gastric cancer (GC). Our study reviews recent advances in immunotherapy in the field of GC and highlights its new prospects as a treatment for GC. Our research reveals China's leadership in this field, as well as new therapeutic strategies such as immune checkpoint inhibitors, cellular immunotherapy, and vaccines. The combined findings highlight the potential of immunotherapy to improve survival and quality of life in patients with stomach cancer. We believe that this study will provide important guidance for the future direction of the GC treatment field.

**Key Words:** Gastric cancer; Immunotherapy; Bibliometrics; Comment; Therapeutic strategies

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** The article is a comprehensive review of immunotherapy for gastric cancer (GC), emphasizing the leadership of immunotherapy in the field of GC. The paper focuses on new strategies such as immune checkpoint inhibitors, cellular immunotherapy, and vaccines, highlighting their potential in improving the survival and quality of life of GC patients. This study provides crucial guidance for the future development direction of GC treatment and valuable insights into emerging therapeutic approaches.

**Citation:** Du QC, Wang XY, Yu H. Gastric cancer immunotherapy: A scientometric and clinical trial review. *World J Gastroenterol* 2024; 30(2): 196-198

**URL:** <https://www.wjgnet.com/1007-9327/full/v30/i2/196.htm>

**DOI:** <https://dx.doi.org/10.3748/wjg.v30.i2.196>

## TO THE EDITOR

I am writing to express my concern regarding the recently published paper titled “Advances and key focus areas in gastric cancer immunotherapy: A comprehensive scientometric and clinical trial review (1999-2023)” by Li *et al*[1] in the *World Journal of Gastroenterology*. The authors have done an exceptional job of providing a thorough analysis of the current status and emerging trends in the field of gastric cancer (GC) immunotherapy. Their findings offer valuable insights into significant advancements within this domain, underscoring its potential to revolutionize treatment approaches for patients with GC.

As a clinician and researcher in the field of gastroenterology, I am convinced that immunotherapy has great potential for GC patients. As the sixth most common cancer worldwide and the third leading cause of cancer-related death, GC highlights the urgent need for innovative treatments[2]. Current treatment modalities, mainly surgery and chemotherapy, have limitations, and the prognosis for advanced GC remains worrisome. The authors’ bibliometric analysis reflects the rapid growth of GC immunotherapy research in recent years and the increasing dominance of China in the number of published articles, which indicates the global interest and commitment to advancing this field. The identification of keywords, such as “tumor microenvironment”, “immunotherapy”, “dendritic cell therapy”, and “microsatellite instability”, highlights the evolving focus areas of GC immunotherapy research.

In addition, I would like to emphasize that international cooperation and communication in this area is essential to accelerate progress in GC immunotherapy. As mentioned in the article, multiple countries and institutions worldwide have contributed to research in the field of GC immunotherapy[3]. Such collaboration helps to share best practices, drive innovation and advance global health. The good news is that combinations of immune checkpoint inhibitors (ICIs), chemotherapy, targeted therapies, and other immunotherapies are becoming major research directions in the future. The authors rightly point out that these new treatment options, including ICIs and chimeric antigen receptor T cells, hold promise for GC patients, with the potential to improve survival and quality of life.

In terms of looking to the future, I think as we develop a deeper understanding of the mechanisms of immunotherapy, we can expect to further increase the level of individualization of treatment. Based on the molecular characteristics of the tumor and individual differences in the immune system, we can predict how a patient will respond to a specific treatment and optimize the outcome by adjusting the treatment regimen. In addition, exploring new immunotherapy targets and strategies, such as tumor-associated antigens and immune cell therapies, will open new avenues for future GC therapies.

## FOOTNOTES

**Author contributions:** Du QC and Wang XY contributed equally in analysis of the data and writing of the manuscript; Yu H designed the article and corrected the paper; and all authors have read and approved the final manuscript.

**Supported by** the Discipline Promotion Program of Shanghai Fourth People’s Hospital, No. SY-XKZT-2020-1021.

**Conflict-of-interest statement:** The authors declare no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** China

**ORCID number:** Qian-Cheng Du 0000-0002-0154-2210; Xin-Yu Wang 0000-0001-8488-7910; Hua Yu 0000-0002-1599-6192.

**S-Editor:** Chen YL

**L-Editor:** A

**P-Editor:** Yu HG

## REFERENCES

- 1 Li YN, Xie B, Zhang Y, He MH, Xing Y, Mu DM, Wang H, Guo R. Advances and key focus areas in gastric cancer immunotherapy: A comprehensive scientometric and clinical trial review (1999-2023). *World J Gastroenterol* 2023; 29: 5593-5617 [PMID: 37970478 DOI: 10.3748/wjg.v29.i40.5593]

- 2 **Sung H**, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**: 209-249 [PMID: 33538338 DOI: 10.3322/caac.21660]
- 3 **Högner A**, Moehler M. Immunotherapy in Gastric Cancer. *Curr Oncol* 2022; **29**: 1559-1574 [PMID: 35323331 DOI: 10.3390/curroncol29030131]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [office@baishideng.com](mailto:office@baishideng.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

